8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Short-term clinical trial of phopranolol in racemic form (Inderal), D-propranolol and placebo in migraine.

      ,
      Acta neurologica Scandinavica
      Wiley

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Propranolol penetrates the blood brain barrier, whereas mainly the racemic form, Inderal, possesses beta-receptor blocking properties. A comparison between d-propranolol and Inderal might therefore indicate the relative importance of the beta blocking properties and possible "central" effects mediated by propranolol and of importance in migraine prophylaxis. The effects of propranolol in racemic form (Inderal) 40 mg q.i.d., d-propranolol 40 mg q.i.d. and placebo were compared in 20 migraine patients. Inderal as well as d-propranolol were significantly superior to placebo. Inderal seemed to be more effective than d-propranolol, but the difference was not statistically significant (P greater than 0.05). The results indicate that beta-receptor blocking properties, but possibly also properties other than the beta-blocking ones, may be of importance for the anti-migraine effect of propranolol.

          Related collections

          Author and article information

          Journal
          Acta Neurol. Scand.
          Acta neurologica Scandinavica
          Wiley
          0001-6314
          0001-6314
          Mar 1976
          : 53
          : 3
          Article
          10.1111/j.1600-0404.1976.tb04342.x
          773081
          c6a32cdb-3ea0-4ccc-9d80-e011f7c35280
          History

          Comments

          Comment on this article